Jin Yang-Guang, Yang Fang, Yang Yu-Rong, Liu Yue, Zhang Yan-Ni, Chen Yu-Xin, Sun Long-Ji, Li Shi-Hao, Wang Wen-Rui, Yang Fan, Li Xing-Ping
College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471023, China.
School of Biological and Food Processing Engineering, Huanghuai University, Zhumadian, 463000, China.
Poult Sci. 2025 Jul 10;104(10):105555. doi: 10.1016/j.psj.2025.105555.
This study evaluated both single and multiple dosing regimens of difloxacin administered via different routes to Sichuan Shelducks: single intramuscular (sIM), intravenous (sIV), oral gavage (sPO), and multiple intramuscular (mIM) and oral gavage (mPO) administrations. The sIV, sPO, and sIM groups received a single dose of difloxacin at 10 mg/kg body weight (BW). The mPO and mIM groups received multiple doses of 10 mg/kg BW at 12-hour intervals: the mPO group received 10 oral doses, and the mIM group received 6 intramuscular doses. Blood samples were collected at various time points from 0 to 48 hours, and plasma concentrations of difloxacin were analyzed using a validated high-performance liquid chromatography (HPLC) method. Pharmacokinetic parameters were calculated using Phoenix software and non-compartmental analysis (NCA). The peak plasma concentration (C) values were 2.05 ± 0.60, 2.26 ± 0.36, 2.81 ± 0.92, and 3.42 ± 0.59 μg/mL for the sPO, sIM, mPO, and mIM groups, respectively, with corresponding peak time (t) of 0.75 ± 0.17, 0.77 ± 0.26, 0.96 ± 0.61, and 0.65 ± 0.33 hours. The PO and IM bioavailability (F) after single administration were 96.00 % ± 22.03 % and 87.62 % ± 9.81 %, respectively. Following single IV administration, difloxacin exhibited extensive distribution, with a volume of distribution (V) of 6.12 ± 3.59 L/kg and a steady-state volume of distribution (V) of 3.18 ± 1.09 L/kg. Difloxacin was eliminated slowly, with terminal half-lives (t) of 10.77 ± 1.78, 4.53 ± 4.44, 4.53 ± 2.97, 6.00 ± 2.00, and 5.33 ± 4.35 hours in the sPO, sIM, sIV, mPO, and mIM groups, respectively. Based on the AUC/MIC ratios, the current single IV and PO dosing regimens, as well as the multiple IM and PO regimens, appear effective against pathogens with MIC values ≤ 0.1 μg/mL. However, the single IM dose of 10 mg/kg BW may be inadequate for treating infections caused by organisms with MIC values > 0.1 μg/mL.
单次肌内注射(sIM)、静脉注射(sIV)、灌胃(sPO),以及多次肌内注射(mIM)和灌胃(mPO)给药。sIV、sPO和sIM组接受10 mg/kg体重(BW)的单剂量双氟沙星。mPO和mIM组以12小时间隔接受10 mg/kg BW的多剂量:mPO组接受10次口服剂量,mIM组接受6次肌内注射剂量。在0至48小时的不同时间点采集血样,并使用经过验证的高效液相色谱(HPLC)方法分析双氟沙星的血浆浓度。使用Phoenix软件和非房室分析(NCA)计算药代动力学参数。sPO、sIM、mPO和mIM组的血浆峰浓度(C)值分别为2.05±0.60、2.26±0.36、2.81±0.92和3.42±0.59μg/mL,相应的达峰时间(t)分别为0.75±0.17、0.77±0.26、0.96±0.61和0.65±0.33小时。单次给药后PO和IM的生物利用度(F)分别为96.00%±22.03%和87.62%±9.81%。单次静脉注射后,双氟沙星表现出广泛分布,分布容积(V)为6.12±3.59 L/kg,稳态分布容积(V)为3.18±1.09 L/kg。双氟沙星消除缓慢,sPO、sIM、sIV、mPO和mIM组的末端半衰期(t)分别为10.77±1.78、4.53±4.44、4.53±2.97、6.00±2.00和5.33±4.35小时。基于AUC/MIC比值,当前的单次静脉注射和PO给药方案,以及多次IM和PO方案,似乎对MIC值≤0.1μg/mL 的病原体有效。然而,10 mg/kg BW的单次IM剂量可能不足以治疗由MIC值>0.1μg/mL的生物体引起的感染。